127 related articles for article (PubMed ID: 38336288)
21. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.
Jin MH; Nam AR; Bang JH; Oh KS; Seo HR; Kim JM; Yoon J; Kim TY; Oh DY
Gastric Cancer; 2021 Sep; 24(5):1003-1020. PubMed ID: 33723720
[TBL] [Abstract][Full Text] [Related]
22. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P
J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Cui Y; Li SB; Peng XC; Wu J; Fu GH
Dig Dis Sci; 2015 Dec; 60(12):3631-41. PubMed ID: 26173505
[TBL] [Abstract][Full Text] [Related]
24. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient.
Wu J; Li L; Qin J; Yan Z; Chen S; Jin T; Xu J
Front Oncol; 2021; 11():780577. PubMed ID: 35155188
[TBL] [Abstract][Full Text] [Related]
26. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
27. CD40×HER2 bispecific antibody overcomes the CCL2-induced trastuzumab resistance in HER2-positive gastric cancer.
Sun W; Wang X; Wang D; Lu L; Lin H; Zhang Z; Jia Y; Nie X; Liu T; Fu W
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851310
[TBL] [Abstract][Full Text] [Related]
28. A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo.
Shu M; Yan H; Xu C; Wu Y; Chi Z; Nian W; He Z; Xiao J; Wei H; Zhou Q; Zhou JX
Sci Rep; 2020 Feb; 10(1):2986. PubMed ID: 32076029
[TBL] [Abstract][Full Text] [Related]
29. ABCB1 C3435T gene polymorphism as a potential biomarker of clinical outcomes in HER2-positive breast cancer patients.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Segura-Pérez AM; Chamorro-Santos C; Vergara-Alcaide E; Castillo-Portellano L; Calleja-Hernández MÁ
Pharmacol Res; 2016 Jun; 108():111-118. PubMed ID: 27137881
[TBL] [Abstract][Full Text] [Related]
30. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.
Shi W; Zhang G; Ma Z; Li L; Liu M; Qin L; Yu Z; Zhao L; Liu Y; Zhang X; Qin J; Ye H; Jiang X; Zhou H; Sun H; Jiao Z
Nat Commun; 2021 May; 12(1):2812. PubMed ID: 33990570
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of PFKFB3 in HER2-positive gastric cancer improves sensitivity to trastuzumab by inducing tumour vessel normalisation.
Yao X; He Z; Qin C; Zhang P; Sui C; Deng X; Fang Y; Li G; Shi J
Br J Cancer; 2022 Sep; 127(5):811-823. PubMed ID: 35637411
[TBL] [Abstract][Full Text] [Related]
32. The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models.
Sanz-Álvarez M; Martín-Aparicio E; Luque M; Zazo S; Martínez-Useros J; Eroles P; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204960
[TBL] [Abstract][Full Text] [Related]
33. Disrupting Circadian Rhythm via the PER1-HK2 Axis Reverses Trastuzumab Resistance in Gastric Cancer.
Wang J; Huang Q; Hu X; Zhang S; Jiang Y; Yao G; Hu K; Xu X; Liang B; Wu Q; Ma Z; Wang Y; Wang C; Wu Z; Rong X; Liao W; Shi M
Cancer Res; 2022 Apr; 82(8):1503-1517. PubMed ID: 35255118
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
35. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
36. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
[TBL] [Abstract][Full Text] [Related]
37. CTTN Overexpression Confers Cancer Stem Cell-like Properties and Trastuzumab Resistance via DKK-1/WNT Signaling in HER2 Positive Breast Cancer.
Moon SJ; Choi HJ; Kye YH; Jeong GY; Kim HY; Myung JK; Kong G
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831511
[TBL] [Abstract][Full Text] [Related]
38. Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
Huynh FC; Nguyen D; Jones FE
Biochem Biophys Res Commun; 2017 Jan; 483(1):739-744. PubMed ID: 27993682
[TBL] [Abstract][Full Text] [Related]
39. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
40. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway.
Eto K; Iwatsuki M; Watanabe M; Ishimoto T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
Int J Cancer; 2015 Apr; 136(7):1537-45. PubMed ID: 25159729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
